explore -WSS

explore

author：entertainment 2025-09-30 23:19:56 - browse：763

A black and white cutout photo of Feng Zhang on the left of a black and white cutout photo of Alex Aravanis. Both photos are placed on top of yellow geometric shapes and a gradient dark blue background. — Researcher Feng Zhang, left, and Alex Aravanis, the CEO of Moonwalk. Illustration: Christine Kao/STAT; Photo: Katherine Taylor for STAT and Business Wire

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand.

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing.

Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： An outdated Medicare rule harms dementia patients with anxiety

WSS

How to use technology to prevent future drug shortages

In same hospitals, Black patients receive fewer opioids than white patients

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Methadone doses haven’t kept up in the age of fentanyl

For Cytokinetics, FDA rejection of heart drug would help, not hinder

For Cytokinetics, FDA rejection of heart drug would help, not hinder

focus

explore

Wikipedia

Sports medicine is finally prioritizing gender equality

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Activists slam private health insurers over coverage restrictions

The best solution to the drug shortages problem

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why failed clinical trials don’t always spell doom for a new drug

The cancer drug shortage isn’t new — and neither are the solutions

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth CEO's Medicaid comments send insurer stocks diving

focus

Naloxone nonprofit donates 200,000 doses after FDA approval

Wegovy trial has doctors encouraged over new possibilities

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Anavex keeps shifting the goalposts in its clinical trials

An outdated Medicare rule harms dementia patients with anxiety

Structure Therapeutics oral GLP

entertainment

explore

Wikipedia

Wikipedia